RESEARCH TRIANGLE PARK, N.C. & SHERBROOKE, Quebec--(BUSINESS WIRE)--Tranzyme Pharma, a leading biopharmaceutical company developing small molecule drugs for the treatment of gastrointestinal and metabolic diseases, announced today that its Senior Vice President of Research and Preclinical Development, Dr. Helmut Thomas, will present results of a preclinical proof-of-concept study with its first-in-class motilin receptor antagonist TZP-201 at the 2007 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics to be held in San Francisco, CA, on October 25, 2007.
